findmyKOL
Clinical trialNCT06576921RecruitingPhase 2Interventional

Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction

SponsorXijing HospitalEnrollment116Immune Checkpoint InhibitorsStomach Neoplasms
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Liu Hong, Ph.D

    Xijing Hospital of Digestive Diseases, Xijing Hospital, Air force Medical University, Changlexi ST 15, Shaanxi Province, 710032, China

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • the Fourth Hospital of Hebei Medical University

    Shijiazhuang, Heibei Province, China

    Recruiting
  • Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi' An, China

    Xi'an, Shaanxi, China

    Recruiting
  • Department of General Surgery, Tangdu Hospital, Air Force Medical University

    Xi'an, Shaanxi, China

    Recruiting
  • Department of General Surgery, the 986th Military Hospital, Air Force Medical University

    Xi'an, Shaanxi, China

    Recruiting
  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
15 Nov 2024
Primary completion
31 May 2026
Completion
30 Sept 2026
Last update posted
23 Apr 2026
Registered enrollment
116
Registry id
NCT06576921

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.